Difference between revisions of "Forodesine (Fodosine)"
Jump to navigation
Jump to search
m |
m |
||
| Line 5: | Line 5: | ||
*[[Peripheral T-cell lymphoma]] | *[[Peripheral T-cell lymphoma]] | ||
| + | ==History of changes in PMDA indication== | ||
| + | *2017-03-30: Initial approval for the treatment of relapsed or refractory [[peripheral T-cell lymphoma]]. | ||
==Also known as== | ==Also known as== | ||
*'''Code name:''' BCX-1777 | *'''Code name:''' BCX-1777 | ||
| Line 17: | Line 19: | ||
[[Category:Peripheral T-cell lymphoma medications]] | [[Category:Peripheral T-cell lymphoma medications]] | ||
| − | [[Category: | + | [[Category:PMDA approved in 2017]] |
[[Category:Orphan drug]] | [[Category:Orphan drug]] | ||
Revision as of 14:36, 9 June 2023
Mechanism of action
From the NCI Drug Dictionary: The hydrochloride salt of the synthetic high-affinity transition-state analogue forodesine. Forodesine binds preferentially to and inhibits purine nucleotide phosphorylase (PNP), resulting in the accumulation of deoxyguanosine triphosphate and the subsequent inhibition of the enzyme ribonucleoside diphosphate reductase and DNA synthesis. This agent selectively causes apoptosis in stimulated or malignant T-lymphocytes.
Diseases for which it is used
History of changes in PMDA indication
- 2017-03-30: Initial approval for the treatment of relapsed or refractory peripheral T-cell lymphoma.
Also known as
- Code name: BCX-1777
- Generic name: immucillin H
- Brand name: Fodosine, Mundesine